Trial Profile
CART-19 recurrent or refractory source B cell acute lymphoblastic leukemia, single center of safety and effectiveness, single arm, open label, phase II clinical study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Sep 2018
Price :
$35
*
At a glance
- Drugs Anti-CD19-chimeric-antigen-receptor-T-cell-therapy-Henan-Huarong-Biotechnology (Primary) ; Cyclophosphamide; Fluorouracil
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 10 Sep 2018 New trial record